Legend Biotech (LEGN) Invested Capital (2021 - 2026)

Legend Biotech (LEGN) has 8 years of Invested Capital data on file, last reported at $266.0 million in Q1 2026.

• Quarterly Invested Capital rose 6.4% year-over-year to $266.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 14.99% YoY) and the FY2025 annual result came in at $319.1 million, up 27.64% from the prior year.
• Invested Capital eased to $266.0 million in Q1 2026, from $319.1 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $398.9 million in Q4 2022 to a low of $126.7 million in Q1 2022.
• A 5-year average of $262.5 million and a median of $250.0 million in 2023 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2022 — Invested Capital soared 69.84% — and 2023, when it slumped 37.33%.
• Tracing LEGN's Invested Capital over 5 years: stood at $398.9 million in 2022, then tumbled by 37.33% to $250.0 million in 2023, then changed by 0.0% to $250.0 million in 2024, then grew by 27.64% to $319.1 million in 2025, then fell by 16.64% to $266.0 million in 2026.
• The last three Invested Capital figures came in at $266.0 million (Q1 2026), $319.1 million (Q4 2025), and $314.8 million (Q3 2025), per Business Quant data.